Aakaar Medical Technologies has announced the appointment of M/s. NAM & ASSOCIATES, a Peer Reviewed Firm of Company Secretaries in Practice, as its Secretarial Auditors for a term of 5 consecutive years. The decision was approved by the Board of Directors at its meeting held on Friday, May 15, 2026, which commenced at 3:35 P.M. IST and concluded at 4:00 P.M. IST, pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

The appointment was made on the recommendation of the Audit Committee and is subject to approval of the shareholders at the ensuing Annual General Meeting. The key details of the appointment are outlined below:

Profile of the Firm

Ms. Neha Marathe, the key professional associated with M/s. NAM & ASSOCIATES, is a fellow member of the Institute of Company Secretaries of India (ICSI) with 10 years of practice experience. Her academic qualifications include a Graduation Degree in Foreign Trade (BFT) and a Post Graduate Diploma in Foreign Trade from Pune University. Her areas of expertise span across:

• Corporate Laws
• Foreign Exchange Laws
• Audit under Company Law and allied laws
• Secretarial Audits of listed and unlisted companies under the Companies Act, 2013
• Corporate restructuring

Ms. Marathe is also registered as an Independent Director on the portal of the Indian Institute of Corporate Affairs.

Regulatory Compliance

The disclosure has been made in accordance with Clause 7 of Para A of Part A of Schedule III of the SEBI Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The announcement was communicated to the National Stock Exchange of India Limited as part of the company's compliance obligations under the applicable SEBI regulations. Company Secretary and Compliance Officer Anoopkumar V. Pillai signed and submitted the disclosure on behalf of Aakaar Medical Technologies Ltd.

Aakaar Medical Technologies Limited has informed the National Stock Exchange of India Limited that its Board of Directors approved the updation and revision of its "Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information" on May 14, 2026. The intimation was made pursuant to Regulation 8(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended. The revised code has been made available on the company's official website at https://aakaarmedical.in/disclosures-as-per-regulation-46-of-the-sebi-lodr-regulations/ .

Policy Overview and Approval Details

The updated code carries Policy No. 07/CS/COC/2024-25 (Revision: 01/2026) and was prepared by Company Secretary Anoopkumar V. Pillai, and approved by Managing Director Dilip Ramesh Meswani and CEO & Director Dr. Rahul Sawakhande. The following table summarises the key administrative details of the policy:

Objective and Scope

The primary objective of the code is to establish a framework for the fair disclosure of events and occurrences that could impact price discovery in the market for the company's securities. The code applies to all disclosures of Unpublished Price Sensitive Information (UPSI) by the company, its subsidiaries, associates, and companies under the same management. It has been framed in compliance with Regulations 3, 8(1), and Schedule 'A' of the SEBI Insider Trading Regulations.

Key Principles of Fair Disclosure

The code mandates that Aakaar Medical Technologies adhere to the following core principles:

• Prompt public disclosure of UPSI that would impact price discovery, as soon as credible and concrete information comes into being
• Uniform and universal dissemination of UPSI to avoid selective disclosure
• Prompt remediation if UPSI is disclosed selectively or inadvertently
• Appropriate response to queries on news reports and requests for verification of market rumors from regulatory authorities
• Maintenance of transcripts or records of analyst meetings and investor relations conferences on the official website
• Need-to-know basis handling of all UPSI for legitimate purposes
• Designation of a senior officer as Investor Relations Officer for dissemination of information and UPSI disclosure

Compliance Officer Responsibilities

The Compliance Officer holds primary responsibility for overseeing all disclosures under the code. Key responsibilities include ensuring regulatory conformity, coordinating with the Board and recognised stock exchanges, verifying the correctness and authenticity of filed information, and monitoring the investor grievance redressal email address. The Compliance Officer is also required to approve disclosures in advance and respond promptly to any selective disclosure of UPSI.

Interactions with Analysts and Investors

The code provides detailed guidelines for interactions with equity research analysts, institutional investors, and research personnel. The company is required to ensure that no UPSI is selectively disclosed during such interactions. For structured communication events, simultaneous audio broadcast over phone, internet, or other suitable media is to be arranged, with recordings made available on the official website for a period of one year. Unanticipated questions raising material issues may be taken on notice, with public announcements made prior to responding if the answer involves UPSI.

Digital Database and Legitimate Purposes

The Board is required to maintain a structured digital database containing the nature of UPSI and the names of persons or entities with whom UPSI has been shared under Regulation 3 of the Insider Trading Regulations, along with their Permanent Account Number (PAN) or any other legally authorised identifier. The database must be maintained with adequate internal controls, including time stamping and audit trails. The code also includes an Annexure A — "Policy for Determination of Legitimate Purposes" — which identifies permissible exceptions for sharing UPSI in the ordinary course of business, including with partners, collaborators, lenders, customers, suppliers, merchant bankers, legal advisors, auditors, insolvency professionals, and other advisors or consultants, provided such sharing is not intended to evade or circumvent the prohibitions under the Insider Trading Regulations.